Where Will TransMedics Group Stock Be in 10 Years?

TransMedics Group is building a vertically integrated logistics network for organ transplantation through its Organ Care System (OCS) and National OCS Program, which extends organ viability during transport. Despite a 45% stock decline following Q1 2026 earnings miss due to margin compression from expansion spending, the company's 21% YoY revenue growth and potential kidney program expansion into Europe position it as a category-defining infrastructure provider in transplant medicine over the next decade.